AIP
HOWL icon

Ameritas Investment Partners’s Werewolf Therapeutics HOWL Stock Holding History

Ameritas Investment Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,987
Closed -$2.9K – 3259
2025
Q1 		$2.9K Hold
2,987
– – ﹤0.01% 3046
2024
Q4 		$4.42K Hold
2,987
– – ﹤0.01% 3045
2024
Q3 		$6.33K Hold
2,987
– – ﹤0.01% 3011
2024
Q2 		$7.29K Buy
+2,987
New +$14.3K ﹤0.01% 3002
2022
Q2 		– Sell
-2,041
Closed -$9K – 3140
2022
Q1 		$9K Hold
2,041
– – ﹤0.01% 2824
2021
Q4 		$24K Buy
2,041
+1,448
+244% +$21.9K ﹤0.01% 2561
2021
Q3 		$10K Hold
593
– – ﹤0.01% 2933
2021
Q2 		$10K Buy
+593
New +$8.12K ﹤0.01% 2930

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameritas Investment Partners's HOWL Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 2,987 shares — an estimated $2.9K sold.

Ameritas Investment Partners first reported a position in HOWL in Q2 2021 and held it in 8 quarters. The position peaked at $24K in Q4 2021. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,987 Werewolf Therapeutics shares in Q2 2025, an estimated $2.9K.
  • Ameritas Investment Partners first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 8 quarters.
  • Ameritas Investment Partners's Werewolf Therapeutics position peaked at $24K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.